Skip to main content
Top
Published in: Pediatric Nephrology 10/2015

01-10-2015 | Original Article

Renal function can be impaired in children with primary hyperoxaluria type 3

Authors: Lise Allard, Pierre Cochat, Anne-Laure Leclerc, François Cachat, Christine Fichtner, Vandréa Carla De Souza, Clotilde Druck Garcia, Marie-Christine Camoin-Schweitzer, Marie-Alice Macher, Cécile Acquaviva-Bourdain, Justine Bacchetta

Published in: Pediatric Nephrology | Issue 10/2015

Login to get access

Abstract

Background

Primary hyperoxaluria type 3 (PH3) is characterized by mutations in the 4-hydroxy-2-oxoglutarate aldolase (HOGA1) gene. PH3 patients are believed to present with a less severe phenotype than those with PH1 and PH2, but the clinical characteristics of PH3 patients have yet to be defined in sufficient detail. The aim of this study was to report our experience with PH3.

Methods

Genetic analysis of HOGA1 was performed in patients with a high clinical suspicion of PH after the presence of mutations in the alanine–glyoxylate aminotransferase gene had been ruled out. Clinical, biochemical and genetic data of the seven patients identified with HOGA1 mutations were subsequently retrospectively reviewed.

Results

Among the seven patients identified with HOGA1 mutations the median onset of clinical symptoms was 1.8 (range 0.4–9.8) years. Five patients initially presented with urolithiasis, and two other patients presented with urinary tract infection. All patients experienced persistent hyperoxaluria. Seven mutations were found in HOGA1, including two previously unreported ones, c.834 + 1G > T and c.3G > A. At last follow-up, two patients had impaired renal function based on estimated glomerular filtration rates (GFRs) of 77 and 83 mL/min per 1.73 m2, respectively.

Conclusions

We found that the GFR was significantly impaired in two of our seven patients with PH3 diagnosed during childhood. This finding is in contrast to the early-impaired renal function in PH1 and PH2 and appears to refute to preliminary reassuring data on renal function in PH3.
Literature
3.
go back to reference Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 123:236–246PubMedCentralCrossRefPubMed Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 123:236–246PubMedCentralCrossRefPubMed
4.
go back to reference Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392–399PubMedCentralCrossRefPubMed Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392–399PubMedCentralCrossRefPubMed
5.
go back to reference Williams EL, Bockenhauer D, van’t Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 27:3191–3195CrossRefPubMed Williams EL, Bockenhauer D, van’t Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 27:3191–3195CrossRefPubMed
6.
go back to reference Belostotsky R, Pitt JJ, Frishberg Y (2012) Primary hyperoxaluria type III–a model for studying perturbations in glyoxylate metabolism. J Mol Med Berl Ger 90:1497–1504CrossRef Belostotsky R, Pitt JJ, Frishberg Y (2012) Primary hyperoxaluria type III–a model for studying perturbations in glyoxylate metabolism. J Mol Med Berl Ger 90:1497–1504CrossRef
7.
go back to reference Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (Formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedCentralCrossRefPubMed Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (Formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedCentralCrossRefPubMed
9.
go back to reference Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21:162–172PubMedCentralCrossRefPubMed Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21:162–172PubMedCentralCrossRefPubMed
10.
go back to reference Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, Dubourg L (2011) Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol 6:552–560PubMedCentralCrossRefPubMed Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, Dubourg L (2011) Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol 6:552–560PubMedCentralCrossRefPubMed
11.
go back to reference Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCentralCrossRefPubMed Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCentralCrossRefPubMed
12.
go back to reference Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP (1997) Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr 131:252–257CrossRefPubMed Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP (1997) Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr 131:252–257CrossRefPubMed
13.
go back to reference Barratt TM, Kasidas GP, Murdoch I, Rose GA (1991) Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 66:501–503PubMedCentralCrossRefPubMed Barratt TM, Kasidas GP, Murdoch I, Rose GA (1991) Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 66:501–503PubMedCentralCrossRefPubMed
14.
go back to reference Cochat P, Hulton S-A, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS, OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736CrossRefPubMed Cochat P, Hulton S-A, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS, OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736CrossRefPubMed
15.
go back to reference Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y (2015) 4-Hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD Rep 15:1–6PubMedCentralPubMed Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y (2015) 4-Hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD Rep 15:1–6PubMedCentralPubMed
16.
go back to reference Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT (2012) 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 1822:1544–1552PubMedCentralCrossRefPubMed Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT (2012) 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 1822:1544–1552PubMedCentralCrossRefPubMed
Metadata
Title
Renal function can be impaired in children with primary hyperoxaluria type 3
Authors
Lise Allard
Pierre Cochat
Anne-Laure Leclerc
François Cachat
Christine Fichtner
Vandréa Carla De Souza
Clotilde Druck Garcia
Marie-Christine Camoin-Schweitzer
Marie-Alice Macher
Cécile Acquaviva-Bourdain
Justine Bacchetta
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 10/2015
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-015-3090-x

Other articles of this Issue 10/2015

Pediatric Nephrology 10/2015 Go to the issue